We are live on
!
Find out more
Viridian Therapeutics
VRDN
VRDN
225 hedge funds and large institutions have $2.21B invested in Viridian Therapeutics in 2026 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 80 increasing their positions, 67 reducing their positions, and 48 closing their positions.
New
Increased
Maintained
Reduced
Closed
19% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 67
2% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 48
2% less funds holding
Funds holding: 229 → 225 (-4)
3.02% less ownership
Funds ownership: 112.97% → 109.95% (-3%)
34% less capital invested
Capital invested by funds: $3.36B → $2.21B (-$1.14B)
41% less call options, than puts
Call options by funds: $6.26M | Put options by funds: $10.7M
54% less funds holding in top 10
Funds holding in top 10: 13 → 6 (-7)
Holders
225
Holders Change
-4
Holders Change %
-1.75%
% of All Funds
2.77%
Holding in Top 10
6
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-53.85%
% of All Funds
0.07%
New
49
Increased
80
Reduced
67
Closed
48
Calls
$6.26M
Puts
$10.7M
Net Calls
-$4.42M
Net Calls Change
-$5.2M
Top Buyers
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$70.3M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$53.8M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
+$50.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$48.7M |
| 5 |
BlackRock
New York
|
+$41.6M |
Top Sellers
| 1 |
PA
Perceptive Advisors
New York
|
-$55.6M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$33.6M |
| 3 |
Jennison Associates
New York
|
-$33.4M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$32.9M |
| 5 |
EP
Eversept Partners
New York
|
-$31.7M |
